[ET Net News Agency, 28 October 2021] Lee's Pharmaceutical Holdings Limited (00950)
said the new drug application (NDA) for Socazolimab to treat recurrent or metastatic
cervical cancer, from China Oncology Focus Limited, a subsidiary of the group, has been
successfully submitted and accepted by the Center for Drug Evaluation (CDE) of the China's
National Medical Products Administration (NMPA) for review. The priority review and
conditional approval applications have also been submitted simultaneously with the NDA.
Socazolimab is a fully human anti PD-L1 monoclonal antibody targeting tumour PD-L1
protein. It can release the "brake" causing by the tumour cell to the immune system. (RC)